vs
Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $93.1M, roughly 1.9× HIVE Digital Technologies Ltd.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -98.1%, a 99.7% gap on every dollar of revenue. On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 5.0%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs -0.2%).
Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HIVE vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $93.1M | $177.4M |
| Net Profit | $-91.3M | $2.9M |
| Gross Margin | -27.1% | — |
| Operating Margin | — | 3.9% |
| Net Margin | -98.1% | 1.6% |
| Revenue YoY | 218.6% | 5.0% |
| Net Profit YoY | -234.0% | — |
| EPS (diluted) | $-0.38 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $93.1M | $196.9M | ||
| Q3 25 | $87.3M | $179.5M | ||
| Q2 25 | $45.6M | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | $29.2M | $187.3M | ||
| Q3 24 | $22.6M | $168.6M | ||
| Q2 24 | $32.2M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-91.3M | — | ||
| Q3 25 | $-15.8M | $5.4M | ||
| Q2 25 | $35.0M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | $68.2M | — | ||
| Q3 24 | $80.0K | $-143.5M | ||
| Q2 24 | $-18.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | -27.1% | 79.5% | ||
| Q3 25 | 4.7% | 80.9% | ||
| Q2 25 | -13.6% | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | -43.7% | 78.7% | ||
| Q3 24 | -66.1% | 76.9% | ||
| Q2 24 | -7.4% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | -82.8% | ||
| Q2 24 | — | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -98.1% | — | ||
| Q3 25 | -18.1% | 3.0% | ||
| Q2 25 | 76.8% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | 233.2% | — | ||
| Q3 24 | 0.4% | -85.1% | ||
| Q2 24 | -56.7% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.38 | $0.05 | ||
| Q3 25 | $-0.07 | $0.12 | ||
| Q2 25 | $0.18 | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | $0.52 | $0.38 | ||
| Q3 24 | $0.00 | $-3.11 | ||
| Q2 24 | $-0.17 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $559.3M | $653.9M |
| Total Assets | $624.0M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | $40.5M | $484.6M | ||
| Q3 24 | $31.7M | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $559.3M | $693.1M | ||
| Q3 25 | $624.6M | $727.2M | ||
| Q2 25 | $560.5M | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | $430.9M | $778.3M | ||
| Q3 24 | $275.5M | $749.6M | ||
| Q2 24 | $268.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $624.0M | $1.3B | ||
| Q3 25 | $693.0M | $1.3B | ||
| Q2 25 | $628.7M | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $478.6M | $1.6B | ||
| Q3 24 | $334.7M | $1.5B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | $43.7M | ||
| Q3 25 | $-10.6M | $60.8M | ||
| Q2 25 | $10.2M | $12.0M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | $-28.5M | $33.1M | ||
| Q3 24 | $-2.2M | $53.9M | ||
| Q2 24 | $-4.4M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | $-55.5M | $31.0M | ||
| Q3 24 | $-34.7M | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | -189.9% | 16.6% | ||
| Q3 24 | -153.4% | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | 92.5% | 1.1% | ||
| Q3 24 | 143.9% | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 0.29× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | -0.42× | — | ||
| Q3 24 | -26.94× | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HIVE
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
